Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 0

The DOI matches its Crossref record; the references it cites are not checked yet.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Ezzedine, Khaled, Lui, Harvey, Eleftheriadou, Viktoria, Desai, Seemal R., Passeron, Thierry, Ringuet, Julien, van Geel, Nanja, Wolkerstorfer, Albert, Lynde, Charles, Augustin, Matthias, López-Estebaranz, José Luis, Grimes, Pearl, Rosmarin, David, Brown, Kurt, Wei, Shaoceng, Karanam, Sunanda, Kornacki, Deanna, Pandya, Amit G.·2026·Nature Medicine
DOI 10.1038/s41591-026-04739-2
Open this paper in CoChat — free account

Abstract

There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-daily povorcitinib (oral, highly selective JAK1 inhibitor) 30 mg in adults with moderate-to-severe NSV (STOP-V1 and STOP-V2). STOP-V1 and STOP-V2 enrolled 467 and 449 patients, respectively. In both studies, the primary endpoint of ≥75% improvement in the facial Vitiligo Area Scoring Index (F-VASI75) at week 52 was met, demonstrating statistically significant and clinically meaningful repigmentation with povorcitinib versus placebo (STOP-V1: 18.9% versus 6.8%; odds ratio, 3.1; 95% confidence interval 1.6–5.9; P = 0.0003; STOP-V2: 18.9% versus 3.1%; odds ratio, 7.5; 95% confidence interval 3.0–18.6; P < 0.0001). Povorcitinib was well tolerated; the percentage of patients with any treatment-emergent adverse event (TEAE) was similar between the povorcitinib and placebo groups in both studies (STOP-V1/STOP-V2, 68.7%/66.7% versus 63.7%/62.7%). The most common TEAEs with povorcitinib were nasopharyngitis (STOP-V1/STOP-V2, 11.2%/11.3% versus placebo, 9.8%/11.1%), acne (10.7%/10.8% versus 3.0%/2.2%) and upper respiratory tract infection (6.9%/14.0% versus 9.0%/10.7%). Serious TEAEs were generally single events, and Janus kinase inhibitor class-specific TEAEs were absent or rare. These results support once-daily povorcitinib as an effective and well-tolerated systemic treatment for adults with moderate-to-severe NSV. ClinicalTrials.gov identifiers: NCT06113445 , NCT06113471 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-026-04739-2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Research works printed but not linked: 46

  1. Bergqvist, C. & Ezzedine, K. Vitiligo: a review. Dermatology 236, 571–592 (2020). · DOI · Paper page
  2. Ezzedine, K., Eleftheriadou, V., Whitton, M. & van Geel, N. Vitiligo. Lancet 386, 74–84 (2015). · DOI
  3. Akl, J. et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health 9, e386–e396 (2024). · DOI
  4. Haulrig, M. B. et al. The global epidemiology of vitiligo: a systematic review and meta-analysis of the incidence and prevalence. J. Eur. Acad. Dermatol. Venereol. 3, 1410–1419 (2024).
  5. Taieb, A. & Picardo, M. Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160–169 (2009). · DOI
  6. Shen, N. et al. Segmental vitiligo: a distinct entity with unique pathogenesis and clinical implications. J. Invest. Dermatol. 146, 1501–1513 (2026). · DOI
  7. Rios-Duarte, J. A., Sanchez-Zapata, M. J. & Silverberg, J. I. Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study. Arch. Dermatol. Res. 315, 2597–2603 (2023). · DOI
  8. Ezzedine, K. et al. Psychosocial effects of vitiligo: a systematic literature review. Am. J. Clin. Dermatol. 22, 757–774 (2021). · DOI · Paper page
  9. Bibeau, K. et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 159, 1124–1128 (2023). · DOI
  10. Picardo, M. et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J. Eur. Acad. Dermatol. Venereol. 36, 1507–1523 (2022). · DOI
  11. Bibeau, K. et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J. Eur. Acad. Dermatol. Venereol. 36, 1831–1844 (2022). · DOI · Paper page
  12. Eleftheriadou, V. et al. Definition of severity and relapse for vitiligo: an international consensus statement. JAMA Dermatol. 162, 515–524 (2026). · DOI
  13. McElroy, J. et al. Understanding the mechanism of disease of vitiligo and the impact on clinical management. J. Dermatol. Physician Assist. 19, 28–35 (2025). · DOI
  14. Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869–1876 (2012). · DOI
  15. Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra223 (2014). · DOI
  16. Richmond, J. M. et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol. 137, 350–358 (2017). · DOI
  17. Seneschal, J. et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force–part 2: specific treatment recommendations. J. Eur. Acad. Dermatol. Venereol. 37, 2185–2195 (2023). · DOI
  18. Zhuo, J. et al. Discovery of the orally bioavailable isoform selective Janus kinase 1 (JAK1) compound povorcitinib (INCB054707) for the treatment of inflammatory and autoimmune diseases. J. Med. Chem. 69, 12830–12852 (2026). · DOI
  19. Pandya, A. G. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 93, 946–955 (2025). · DOI
  20. Kitchen, H. et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol. Ther. (Heidelb.) 12, 1623–1637 (2022). · DOI
  21. Ezzedine, K. et al. Psychometric properties and meaningful change thresholds of the Vitiligo Area Scoring Index. JAMA Dermatol. 161, 39–46 (2025). · DOI
  22. Prajapati, V. H. et al. Canadian consensus guidelines for the management of vitiligo. Dermatol. Ther. (Heidelb.) 15, 1351–1369 (2025). · DOI
  23. Phan, K., Phan, S., Shumack, S. & Gupta, M. Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis. J. Dermatolog. Treat. 33, 173–177 (2022). · DOI
  24. Pandya, A. G. et al. Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo. J. Invest. Dermatol. 146, 1867–1875 (2026). · DOI
  25. Seneschal, J. & Boniface, K. Vitiligo: current therapies and future treatments. Dermatol. Pract. Concept. 13, e2023313S (2023). · DOI
  26. Kirby, J. S. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 90, 521–529 (2024). · DOI
  27. Porter, M. L. et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat. Med. 32, 3071–3081 (2026). · DOI
  28. Bieber, T. et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J. Eur. Acad. Dermatol. Venereol. 35, 476–485 (2021). · DOI · Paper page
  29. Sandborn, W. J. et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin. Gastroenterol. Hepatol. 17, 1541–1550 (2019). · DOI
  30. Burmester, G. R. et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9, e002735 (2023). · DOI
  31. Nash, P. et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann. Rheum. Dis. 80, 71–87 (2021). · DOI
  32. Ezzedine, K. et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J. Am. Acad. Dermatol. 88, 395–403 (2023). · DOI
  33. Ezzedine, K. et al. Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream. J. Eur. Acad. Dermatol. Venereol. 39, e378–e380 (2024).
  34. Ingrassia, J. P. et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 160, 28–36 (2024). · DOI
  35. Huang, F. et al. Efficacy and safety of Janus kinase inhibitors in patients with vitiligo: a systematic review and meta-analysis. Clin. Pharmacol. Ther. 117, 659–669 (2025). · DOI
  36. Passeron, T. et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EClinicalMedicine 73, 102655 (2024). · DOI
  37. Passeron, T. et al. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet 408, 636–648 (2026). · DOI
  38. Neubauer, H. et al. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409 (1998). · DOI
  39. Facheris, P. et al. JAK inhibitor safety in atopic dermatitis and alopecia areata: a 4.5-year real-world retrospective cohort study. Dermatol. Ther. (Heidelb.) 16, 4305–4324 (2026). · DOI
  40. Xiong, G. et al. Weight gain secondary to the use of oral Janus kinase inhibitors: a systematic review and meta-analysis. JAAD Int. 19, 1–9 (2024). · DOI
  41. Rosmarin, D. et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N. Engl. J. Med. 387, 1445–1455 (2022). · DOI
  42. Harris, J. E. et al. Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study. Br. J. Dermatol. 194, 591–593 (2026). · DOI
  43. Hamzavi, I. et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch. Dermatol. 140, 677–683 (2004). · DOI
  44. Batchelor, J. M. et al. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. Br. J. Dermatol. 174, 386–394 (2016). · DOI
  45. Lilly, E. et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J. Am. Acad. Dermatol. 69, e11–e18 (2013). · DOI
  46. Zigmond, A. S. & Snaith, R. P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67, 361–370 (1983). · DOI · Paper page

Metadata

Authors
Ezzedine, K., Lui, H., Eleftheriadou, V., Desai, S. R., Passeron, T., Ringuet, J., van Geel, N., Wolkerstorfer, A., Lynde, C., Augustin, M., López-Estebaranz, J. L., Grimes, P., Rosmarin, D., Brown, K., Wei, S., Karanam, S., Kornacki, D., & Pandya, A. G.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2026-11-02
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/s41591-026-04739-2
Cited by
0
Language
en
Licence
Funders
Incyte Corporation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials. https://app.cochat.ai/papers/10.1038/s41591-026-04739-2
The paper
Ezzedine, K., Lui, H., Eleftheriadou, V., Desai, S. R., Passeron, T., Ringuet, J., van Geel, N., Wolkerstorfer, A., Lynde, C., Augustin, M., López-Estebaranz, J. L., Grimes, P., Rosmarin, D., Brown, K., Wei, S., Karanam, S., Kornacki, D., & Pandya, A. G. (2026). Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials. Nature Medicine. https://doi.org/10.1038/s41591-026-04739-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.